Active Removal of IntraCerebral Hematoma Via Active Irrigation
- Conditions
- Cerebral HemorrhageIntraventricular Hemorrhage
- Interventions
- Device: IRRAflowDevice: EVD
- Registration Number
- NCT05118997
- Lead Sponsor
- IRRAS
- Brief Summary
Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.
- Detailed Description
The ARCH study is an international prospective, controlled, randomized, multicenter study to evaluate the hypothesis that active irrigation with IRRAflow® will reduce the time needed for clearance of intraventricular and intracerebral blood from intraventricular and intracerebral space compared with passive drainage and administration of tPA. This might affect the patient neurological outcome assessed by GCS and mRankin scale.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
-
Age >18 years of age
-
Need of EVD
-
Active treatment
-
Signed informed consent obtained
a. Based on institutional and country laws
-
Spontaneous ICH with maximum 30 square cm's
-
If needed, normal coagulation profile (PT, PTT, platelet count)
-
Treatment within 72 hours of ictus
-
Ability to administer 2.0 mg of tPA per day for 3 days
- Age < 18 years
- No need of EVD
- Patient has fixed and dilated pupils
- Coagulopathy uncorrectable
- Vascular pathology (e.g. Aneurysm involvement, AVM involvement)
- Pregnant women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Treatment Arm #1 IRRAflow IRRAflow with manual tPA administration followed by Active Fluid Exchange Treatment Arm #2 IRRAflow IRRAflow with continuous infusion of tPA combined with Active Fluid Exchange Treatment Arm #3 EVD Standard EVD with manual tPA administration
- Primary Outcome Measures
Name Time Method Efficacy and safety of evacuation of intraventricular hematoma by Active External Ventricular Drainage (IRRAflow) with tPA administration compared to Passive External Ventricular Drainage (EVD) with tPA administration. Intra-procedure Efficacy is defined as the efficiency of each arm to remove the hematoma (70% cm3). Safety is measured as the frequency of bacterial central nervous system (measures as positive bacterial growth in cerebrospinal fluid), symptomatic brain bleeds (clinical symptoms drop in modified Rankin scale), and mortality (death).
Radiographic evaluation of ventricular blood removal as measured by head CT scan Intra-procedure Change in blood volume (cm3) measured between stability scan and end of treatment scan.
Comparison of patient outcome between groups at as measured by the Glasgow Coma Scale, extended Glasgow Outcome Scale, modified Rankin Scale. 0-30 days post discharge from hospital Defined as the comparison of patients outcomes between the three groups as measured by Glasgow Coma Scale, extended Glasgow Outcome Scale, and modified Rankin Scale.
- Secondary Outcome Measures
Name Time Method Procedural Success Intra-Procedural Less than or equal to 30% residual clot burden in the ventricular system
Technical Success Intra-Procedural Percent obstruction of the IRRAflow catheter and EVD catheter
Safety - Catheter misplacement Intra-Procedural Measurement of if the catheter needs to be re-inserted or re-positioned.
Safety - Infection Intra-Procedural Comparison of rate of infection as measured by routine cerebrospinal fluid (CSF) analysis
Safety - Bleeding events Intra-Procedural Comparison of new bleeding events on routine neuroimaging
Trial Locations
- Locations (1)
Helsinki University
🇫🇮Helsinki, Finland